Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Small extracellular vesicles as system-level regulators and predictive biomarkers in breast cancer progression and chemoresistance

Li J., Cheng H., Liu X.

Narrative Review on Immune Modulation, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pharmacol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41939850
PMCID
PMC13046706
DOI
10.3389/fphar.2026.1804877

Abstract (original English)

Small extracellular vesicles (sEVs) play a pivotal regulatory role in intercellular communication within breast cancer, coordinating tumor growth, microenvironment remodeling, immune modulation, and therapeutic response. Beyond serving as passive carriers of biomolecules, mounting evidence indicates that sEVs actively orchestrate the dynamic evolution of the tumor ecosystem through cargo specificity and cell-of-origin-dependent mechanisms. We synthesize recent research advances (2021-2025) to elucidate how nucleic acids, proteins, and lipids carried by sEVs integrate into key processes in breast cancer, including oncogenic signaling, epithelial-mesenchymal transition (EMT), metastasis microenvironment formation, immune evasion, and therapeutic resistance. We further highlight how their specificity and cellular origin provide a unified framework for reconciling reported functional heterogeneity in sEVs across studies. Building on this, we discuss emerging evidence demonstrating sEVs' role in reshaping tumor-immune and therapeutic ecosystems, promoting immune evasion, and facilitating horizontal transmission of drug-resistant phenotypes. Finally, we evaluate the translational potential of sEVs as biomarkers and therapeutic targets, proposing a conceptual framework for integrating sEV profiling into precision oncology strategies. This review positions sEVs as central regulators of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research